A brief dive into the phenomenon of cisplatin resistance in non-small-cell lung cancer

Maciej Sobczak

doi:10.18778/1730-2366.16.12

Authors

Maciej Sobczak University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biophysics, Pomorska 141/143, 90-236 Lodz, Poland https://orcid.org/0000-0002-7377-6796

DOI:

https://doi.org/10.18778/1730-2366.16.12

Keywords:

non-small-cell lung cancer, cisplatin, cisplatin resistance

Abstract

Lung cancer is one of the most lethal types of cancer due to a lack of proper treatment. The rare presence of molecular therapy targets forces the use of platinum-based drugs. Cisplatin, approved by the USA as an anticancer therapy in the 1970s, is still one of the most prominent therapies against lung cancer. Unfortunately, the biggest limitation of cisplatin-based therapy is the development of cisplatin resistance. Cancer cells overcome the vast DNA damage caused by the drug in a variety of ways such as detoxication and extracellular transport of the drug, enhanced repair mechanisms, omitting apoptosis and epigenetic alterations. Chemotherapy resistance is an issue that so far cannot be dealt with. Nevertheless, better understanding of the molecular pathways behind cisplatin resistance brings hope for better therapy outcomes in lung cancer patients.

Downloads

Download data is not yet available.

References

Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., Patrick, S.M. 2010. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst), 9: 745–753. DOI: https://doi.org/10.1016/j.dnarep.2010.03.010

Dela Cruz, C.S., Tanoue, L.T., Matthay, R.A. 2011. Lung cancer: Epidemiology, etiology, and prevention. Clinics in Chest Medicine, 32(4): 605–644. DOI: https://doi.org/10.1016/j.ccm.2011.09.001

Fadejeva, I., Olschewski, H., Hrzenjak, A. 2017. MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget, 8(70): 115754–115773. DOI: https://doi.org/10.18632/oncotarget.22975

Fennell, D.A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D.C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., Ferry, D. 2016. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews, 44: 42–50. DOI: https://doi.org/10.1016/j.ctrv.2016.01.003

Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., Kroemer, G. 2012. Molecular mechanisms of cisplatin resistance. Oncogene, 31(15): 1869–1883. DOI: https://doi.org/10.1038/onc.2011.384

Gąsiorkiewicz, B.M., Koczurkiewicz-Adamczyk, P., Piska, K., Pękala, E. 2021. Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer. Investigation New Drugs, 39: 538–563. DOI: https://doi.org/10.1007/s10637-020-01032-y

He, Y., Chen, D., Yi, Y., Zeng, S., Liu, S., Li, P., Xie, H., Yu, P., Jiang, G., Liu, H. 2020. Histone deacetylase inhibitor sensitizes ERCC1-high non-small-cell lung cancer cells to cisplatin via regulating miR-149. Molecular Therapy – Oncolytics, 17: 448–459. DOI: https://doi.org/10.1016/j.omto.2020.05.001

Hu, C., Zhang, M., Moses, N., Hu, C.-L., Polin, L., Chen, W., Jang, H., Heyza, J., Malysa, A., Caruso, J.A., Xiang, S., Patrick, S., Stemmer, P., Lou, Z., Bai, W., Wang, C., Bepler, G., Zhang, X.M. 2020. The USP10-HDAC6 axis confers cisplatin resistance in non-small cel lung cancer lacking wild-type p53. Cell Death & Disease, 11: 1–18. DOI: https://doi.org/10.1038/s41419-020-2519-8

Lan, D., Wang, L., He, R., Ma, J., Bin, Y., Chi, X., Chen, G., Cai, Z. 2018. Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells. American Journal of Translational Research, 10: 1295–1309.

O’Byrne, K.J., Barr, M.P., Gray, S.G. 2011. The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer. Cancers (Basel), 3(1): 1426–1453. DOI: https://doi.org/10.3390/cancers3011426

Peklak-Scott, C., Smitherman, P.K., Townsend, A.J., Morrow, C.S. 2008. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Molecular Cancer Therapeutics, 7(10): 3247–3255. DOI: https://doi.org/10.1158/1535-7163.MCT-08-0250

Pizzorno, J. 2014. Glutathione! Integrative Medicine (Encinitas), 13: 8–12.

Rocha, C.R.R., Silva, M.M., Quinet, A., Cabral-Neto, J.B., Menck, C.F.M. 2018. DNA repair pathways and cisplatin resistance: An intimate relationship. Clinics (Sao Paulo), 73(Suppl 1): e478s. DOI: https://doi.org/10.6061/clinics/2018/e478s

Siegel, R.L., Miller, K.D., Fuchs, H.E., Jemal, A. 2021. Cancer statistics, 2021. C.A. Cancer Journal of Clinicians, 71: 7–33. DOI: https://doi.org/10.3322/caac.21654

Sun, D.M., Tang, B.F., Li, Z.X., Guo, H.B., Cheng, J.L., Song, P.P., Zhao, X. 2018. miR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway. Scientific Reports, 8: 1–9. DOI: https://doi.org/10.1038/s41598-018-26381-w

Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., Wilson, M. 2018. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46: D1074–D1082. DOI: https://doi.org/10.1093/nar/gkx1037

Wu, H.M., Jiang, Z.F., Ding, P.S., Shao, L.J., Liu, R.Y. 2015. Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. Scientific Reports, 5: 12291. DOI: https://doi.org/10.1038/srep12291

Yun, C.W., Lee, S.H. 2018. The roles of autophagy in cancer. International Journal of Molecular Sciences, 19(11): 3466. DOI: https://doi.org/10.3390/ijms19113466

Zappa, C., Mousa S.A. 2016. Non-small cell lung cancer: Current treatment and future advances. Translational Lung Cancer Research, 5: 288–300. DOI: https://doi.org/10.21037/tlcr.2016.06.07